CCR4 and cancer: In Pan02 and CT26 mouse tumor models, CCR4 blockade decreases Treg migration, thereby improving ICB performance, particularly in tumors with high baseline CCR4 ligand expression or in those where ICB treatment upregulates CCR4 ligands.384 Consequently, inhibiting CCR4 not only reduces Treg frequency but also amplifies the efficacy of ICB, highlighting the importance of CCR4-dependent Treg recruitment in immunotherapy resistance and supporting the use of CCR4 inhibitors alongside ICB in cancer treatment strategies.384